Secarna Pharmaceuticals announces publication of new preclinical data showing strong potential of LNAplus™-based ASOs to effectively treat diabetic kidney disease

Secarna Pharmaceuticals and Evotec expand strategic partnership in the field of antisense drug discovery

Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity

Secarna Pharmaceuticals appoints Alexander Gebauer, MD, PhD as CEO and Managing Director

Data published in Molecular Diagnostics & Therapy demonstrate how Secarna’s powerful bioinformatics generate improved LNA-modified antisense oligonucleotide therapies

Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals’ LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids

Secarna Pharmaceuticals and Denali Therapeutics enter into research and option agreement to develop novel antisense therapies in the field of neurodegenerative diseases

Secarna Pharmaceuticals and Evotec form strategic partnership in the field of antisense therapy

Secarna Pharmaceuticals enters into cooperation with Guangzhou’s Sun Yat-sen University to develop a treatment for SARS-CoV-2 viral infections

BIO-Europe Spring® 2018 / Secarna MD Jonas Renz on standing out in a crowd